Key messages
- Nella pratica clinica l’interruzione di un trattamento può non risultare in un’immediata cessazione del controllo della malattia: alcuni pazienti, infatti, manifestano una prolungata risposta terapeutica.
- La presente analisi post hoc dei trial clinici di fase 3 UNCOVER-1 e -2 ha analizzato l’intervallo temporale di perdita di risposta al trattamento nei pazienti affetti da psoriasi con pregressa risposta a ixekizumab in un periodo di trattamento di 12 settimane, successivamente randomizzati con il placebo per 48 settimane.
- Un piccolo sottogruppo di pazienti ha mantenuto alti livelli di controllo della malattia fino alla 60ma settimana.
Abstract
In clinical practice, interruption of treatment may not result in immediate cessation of disease control, and some patients even experience sustained treatment response following treatment interruption. This post hoc analysis of UNCOVER-1 and -2 Phase 3 clinical trials characterized the time to loss of treatment response in patients with psoriasis who responded to ixekizumab through a 12-week treatment period, and who were then re-randomized to placebo for the following 48 weeks. For those with static Physician Global Assessment [sPGA]0/1 and Psoriasis Area and Severity Index [PASI]90 at Week 12, the median time to loss of PASI90 was 16.1 weeks (95% confidence interval 12.7-16.4). For those with PASI100 at Week 12, the median time to loss of PASI100 was 12.1 weeks (95% confidence interval 9.0-13.0). A small subset of patients maintained high levels of disease control through Week 60. This study adds to the growing body of evidence on sustained treatment response following treatment interruption.